Products
Alethia is focusing on bone loss in acute disorders, invasive carcinomas and on cancer-associated epithelial-to-mesenchymal transition, three areas for which there are very few therapeutic options.
AB-25E9 – inhibition of bone degradation
- Alethia is developing a first-in-class bone antiresorptive for the treatment of bone loss in acute disorders such a hypercalcemia of malignancy, bone and cartilage loss in inflammatory disorders and severe osteoporosis. Read more about AB-25E9
AB-3A4 – invasive carcinomas
- Alethia is developing a therapeutic monoclonal antibody for the treatment of ovarian cancer and other invasive carcinomas such as triple-negative breast tumors and renal cancer. AB-3A4 is an IgG1 monoclonal antibody against KAAG-1, a cell-surface protein involved in tumor invasion. Read more about AB-3A4
AB-16B5 – inhibition of EMT
- Alethia is developing an inhibitor of EMT for the treatment of invasive carcinomas. AB-16B5 is a humanized IgG2 antibody against an EMT-inducing form of secreted clusterin (sCLU). AB-16B5 very efficiently blocks EMT and pre-clinical data indicate that animals xenografted with various carcinoma cells show an increase of response to standard of care chemotherapy as well as a reduction of invasion. Read more about AB-16B5
News
- May 16, 2013 Alethia Biotherapeutics Announces the Issuance of a United States Patent for Monoclonal Antibodies Targeting Secreted Clusterin for Inhibition of EMT Alethia 130516 EN...
- February 28, 2013 Alethia Biotherapeutics Announces Notice of Allowance of a United States Patent for Monoclonal Antibodies Targeting Secreted Clusterin for Inhibition of EMT Alethia 130228 EN...
- February 19, 2013 Alethia Biotherapeutics Announces Issuance of a Japanese Patent for Monoclonal Antibodies Targeting Siglec-15 Alethia 130219 EN...
Events
- March 11-13, 2013 Alethia Biotherapeutics to be part of the BIO Europe Spring 2013 Annual International Partnering Conference in Barcelona, Spain. Yves Cornellier and Mario Filion will be in attendance....
- October 12-15, 2012 Alethia Biotherapeutics to be part of the ASBMR 2012 Annual Meeting in Minneapolis, Minnesota, USA. Drs. Julie Laurin and Gilles Tremblay will be in attendance....
- March 31 - April 4, 2012 Alethia Biotherapeutics to present at the AACR Annual Meeting in Chicago, IL, USA. "The EMT inhibitor AB-16B5 interacts with specific isoforms of secreted clusterin". Mario Filion and Gilles Tremblay will be in attendance....